aTyr Pharma (NASDAQ:LIFE) Stock Rating Upgraded by HC Wainwright

Share on StockTwits

HC Wainwright upgraded shares of aTyr Pharma (NASDAQ:LIFE) from a neutral rating to a buy rating in a report published on Monday, AnalystRatings.com reports. They currently have $13.00 price target on the biotechnology company’s stock.

A number of other analysts also recently weighed in on the stock. ValuEngine downgraded shares of aTyr Pharma from a buy rating to a hold rating in a report on Monday, July 20th. Zacks Investment Research downgraded shares of aTyr Pharma from a buy rating to a hold rating in a report on Wednesday, June 24th. Finally, Oppenheimer restated a buy rating and issued a $8.00 target price on shares of aTyr Pharma in a report on Tuesday, June 16th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $8.95.

Shares of NASDAQ LIFE opened at $4.57 on Monday. The company has a current ratio of 4.47, a quick ratio of 4.47 and a debt-to-equity ratio of 0.05. The firm’s fifty day moving average is $4.24 and its two-hundred day moving average is $3.79. aTyr Pharma has a 52-week low of $2.13 and a 52-week high of $7.62.

aTyr Pharma (NASDAQ:LIFE) last announced its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04. aTyr Pharma had a negative net margin of 190.06% and a negative return on equity of 51.92%. On average, research analysts forecast that aTyr Pharma will post -2.11 earnings per share for the current year.

In other news, CEO Sanjay Shukla purchased 6,000 shares of the company’s stock in a transaction that occurred on Friday, June 19th. The stock was purchased at an average cost of $4.27 per share, with a total value of $25,620.00. Following the purchase, the chief executive officer now owns 7,291 shares in the company, valued at $31,132.57. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 9.44% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Two Sigma Advisers LP purchased a new position in shares of aTyr Pharma during the 1st quarter worth about $102,000. Two Sigma Investments LP purchased a new stake in aTyr Pharma in the 1st quarter valued at about $180,000. Federated Hermes Inc. raised its holdings in shares of aTyr Pharma by 171.4% in the 1st quarter. Federated Hermes Inc. now owns 1,615,000 shares of the biotechnology company’s stock valued at $4,522,000 after purchasing an additional 1,019,928 shares in the last quarter. UBS Group AG raised its holdings in shares of aTyr Pharma by 1,002.1% in the 1st quarter. UBS Group AG now owns 37,999 shares of the biotechnology company’s stock valued at $106,000 after purchasing an additional 34,551 shares in the last quarter. Finally, Alyeska Investment Group L.P. bought a new stake in shares of aTyr Pharma in the 1st quarter valued at about $2,067,000. 56.10% of the stock is owned by hedge funds and other institutional investors.

About aTyr Pharma

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD.

Featured Article: The role of implied volatility with call option volume

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply